Immunome, Inc.
IMNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -35.5% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,674.1% | -199.7% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,240.4% | -761.9% | – | – |
| EPS Diluted | -5 | -5.38 | -3.09 | -2.14 |
| % Growth | 7.1% | -74.1% | -44.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |